Vanderbilt University Medical Center
Nashville, Tennessee, 37212, United States
NCT Number: NCT04559529
The purpose of this study is to test whether administration of levetiracetam (LEV), a commonly used anti-epileptic that alters neurotransmitter release, can reduce hippocampal hyperactivity in people with psychotic disorders. Specifically, the investigators will utilize two functional magnetic resonance imaging (MRI) techniques: 1) blood-oxygen-level-dependent (BOLD) contrast will assess activity with a visual scene processing task that engages the anterior hippocampus and 2) arterial spin labeling (ASL) will assess baseline activity. Previous studies in people with psychotic disorders have shown that the hippocampus is hyperactive and more activity correlates with worsening of clinical symptoms. Therefore, the aim of this study is to use an intervention to further understand the underlying mechanisms of the hippocampus in psychosis.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 2
Nashville, Tennessee, 37212, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion criteria
for psychosis subjects
Inclusion criteria
for healthy controls
----
Exclusion criteria
Exclusion criteria
for psychosis subjects
Exclusion criteria
for healthy controls
All of the above and in addition:
The levetiracetam pill will look just like the placebo pill.
Other names: Keppra
The placebo pill will look just like the levetiracetam pill, but does not contain any levetiracetam.
Time frame: 2 hours after LEV administration
ASL signal after LEV, using Magnetic Resonance Imaging (MRI) scanning of the brain. ASL measures cerebral blood flow, which is linked to neuronal metabolism and functions as a proxy for neuronal activity.
Time frame: 2 hours after placebo administration
ASL signal after placebo, using Magnetic Resonance Imaging (MRI) scanning of the brain. ASL measures cerebral blood flow, which is linked to neuronal metabolism and functions as a proxy for neuronal activity.
Time frame: 2 hours after LEV administration
BOLD signal after LEV, using Magnetic Resonance Imaging (MRI) scanning of the brain. This method reflects changes in oxygenation of blood in the brain during a scene-processing task that engages, or recruits, the hippocampus.
Time frame: 2 hours after placebo administration
BOLD signal after placebo, using Magnetic Resonance Imaging (MRI) scanning of the brain. This method reflects changes in oxygenation of blood in the brain during a scene-processing task that engages, or recruits, the hippocampus.
Vanderbilt University Medical Center
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07165821
Behavior, Health Behavior
Nai Muang, Changwat Ubon Ratchathani, Thailand
View Trial DetailsNCT04738123
Mental Disorders, Psychotic Disorders
Bentonville, Arkansas, United States
View Trial DetailsNCT04748679
Mental Disorders, Persecutory Delusion
Nashville, Tennessee, United States
View Trial DetailsNCT04659161
Mental Disorders, Psychotic Disorders
Little Rock, Arkansas, United States
View Trial Details